Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
Clinical implications of T cell exhaustion for cancer immunotherapy
A Chow, K Perica, CA Klebanoff… - Nature reviews Clinical …, 2022 - nature.com
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm …
Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin… - Nature medicine, 2022 - nature.com
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented
responses in patients with high-risk hematologic malignancies. However, up to 60% of …
responses in patients with high-risk hematologic malignancies. However, up to 60% of …
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management
S Susanibar‐Adaniya, SK Barta - American journal of …, 2021 - Wiley Online Library
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
J Westin, LH Sehn - Blood, The Journal of the American Society …, 2022 - ashpublications.org
The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …